{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:27Z","timestamp":1791492687189,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019155","name":"Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","award":["2022-LCYJ-MS-04"],"award-info":[{"award-number":["2022-LCYJ-MS-04"]}],"id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.semarthrit.2026.152942","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:49:57Z","timestamp":1770709797000},"page":"152942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Serological Stratification by Anti-Ro52 and Anti-Ro60 Profiles Reveals Distinct Systemic Phenotypes in Primary Sj\u00f6gren's Disease"],"prefix":"10.1016","volume":"77","author":[{"given":"Qingfeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liupan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daidi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.152942_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0002","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","article-title":"Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients","volume":"752","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for primary Sj\u00f6gren's Syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"691","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0004","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1172\/JCI115003","article-title":"Molecular definition and sequence motifs of the 52-kD component of human SS-A\/Ro autoantigen","volume":"871","author":"Chan","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS-A autoantibody system","volume":"87","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0006","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1172\/JCI114013","article-title":"Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A\/Ro ribonucleoprotein autoantigen","volume":"834","author":"Ben-Chetrit","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0007","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nsmb1156","article-title":"Structural and biochemical basis for misfolded RNA recognition by the Ro autoantigen","volume":"1311","author":"Fuchs","year":"2006","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0008","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3389\/fimmu.2019.02049","article-title":"TRIM21-From intracellular immunity to therapy","volume":"10","author":"Foss","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10409238.2019.1608902","article-title":"Ro60 and Y RNAs: structure, functions, and roles in autoimmunity","volume":"542","author":"Boccitto","year":"2019","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102724","article-title":"Anti-Ro60 and anti-Ro52\/TRIM21: two distinct autoantibodies in systemic autoimmune diseases","volume":"124","author":"Lee","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105895","article-title":"Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sj\u00f6gren syndrome","volume":"163","author":"Buvry","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0012","article-title":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","volume":"213","author":"Decker","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"Suppl 1264","key":"10.1016\/j.semarthrit.2026.152942_bib0013","first-page":"134","article-title":"Skopouli FN anti-Ro52 and\/or anti-Ro60 immune reactivity: autoantibody and disease associations","volume":"38","author":"Zampeli","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0014","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Crow MK Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"525","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9195157","article-title":"Clinical significance of different profiles of anti-ro antibodies in connective tissue diseases","volume":"2023","author":"Yang","year":"2023","journal-title":"J Immunol Res"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0016","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2019.00444","article-title":"Diagnostic utility of separate Anti-Ro60 and Anti-Ro52\/TRIM21 antibody detection in autoimmune diseases","volume":"10","author":"Robbins","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0017","article-title":"Feng X Anti-Ro52 antibodies in clinical practice: A single-centre experience","volume":"753","author":"Wu","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0018","article-title":"Isolated anti-Ro52 identifies a severe subset of Sj\u00f6gren's syndrome patients","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0019","article-title":"The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus","author":"Liao","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"616","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"761","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0022","article-title":"EULAR Sj\u00f6gren's syndrome disease activity index (ESSDAI): a user guide","volume":"11","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0023","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10067-022-06426-2","article-title":"Renal tubular acidosis and associated factors in patients with primary Sj\u00f6gren's syndrome: a registry-based study","volume":"422","author":"Zhang","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0024","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kev223","article-title":"Renal involvement in primary Sj\u00f6gren's syndrome","volume":"549","author":"Evans","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0025","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sj\u00f6gren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"5412","author":"Ramos-Casals","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200001000-00001","article-title":"Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: classification and diagnostic criteria","volume":"241","author":"Katzenstein","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0027","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keh407","article-title":"Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome","volume":"441","author":"Ramos-Casals","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0028","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","article-title":"Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients","volume":"535","author":"Baldini","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0029","first-page":"1","article-title":"Identification of inflammatory markers as indicators for disease progression in primary Sj\u00f6gren syndrome","volume":"351","author":"Li","year":"2024","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren's Syndrome","volume":"37810","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0031","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2665-9913(24)00183-8","article-title":"Identification and evolution of predictors of Sj\u00f6gren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study","volume":"610","author":"Goules","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0032","article-title":"Combined anti-Ro52\/TRIM21 and anti-Ro60\/SSA antibodies are associated with increased Sj\u00f6gren's disease severity through interferon pathway activation","author":"Bettacchioli","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0033","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/acr.24597","article-title":"Antibodies to both Ro52 and Ro60 for identifying Sj\u00f6gren's Syndrome patients best suited for clinical trials of disease-modifying therapies","volume":"749","author":"Arma\u011fan","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0034","article-title":"Prevalence of anti-Ro52-kDa\/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: data from a French cohort, a systematic review and meta-analysis","volume":"235","author":"Martel","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0035","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","article-title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"6111","author":"Gui","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0036","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00296-010-1790-x","article-title":"Lee SW the prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sj\u00f6gren's syndrome","volume":"322","author":"Song","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0037","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fimmu.2019.00325","article-title":"Regulating IRFs in IFN driven disease","volume":"10","author":"Jefferies","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0038","article-title":"TRIpartite motif 21 (TRIM21) differentially regulates the stability of interferon regulatory factor 5 (IRF5) isoforms","volume":"98","author":"Lazzari","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0039","article-title":"Self protection from anti-viral responses\u2013Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors","volume":"57","author":"Higgs","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.aac7442","article-title":"The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression","volume":"3506259","author":"Hung","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0041","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fimmu.2020.00098","article-title":"TRIM21 Dysfunction enhances aberrant B-cell differentiation in autoimmune pathogenesis","volume":"11","author":"Kunishita","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0042","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","article-title":"Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors","volume":"4166881","author":"Leadbetter","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2026.152942_bib0043","doi-asserted-by":"crossref","first-page":"39789","DOI":"10.1074\/jbc.M112.383000","article-title":"Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands","volume":"28747","author":"Green","year":"2012","journal-title":"J Biol Chem"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:42:09Z","timestamp":1791492129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"alternative-id":["S0049017226000314"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152942","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological Stratification by Anti-Ro52 and Anti-Ro60 Profiles Reveals Distinct Systemic Phenotypes in Primary Sj\u00f6gren's Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152942"}}